Evidence map›Paper›PMID 28903780›Full record

ArticleParticle and fibre toxicology2017

Stat-6 signaling pathway and not Interleukin-1 mediates multi-walled carbon nanotube-induced lung fibrosis in mice: insights from an adverse outcome pathway framework.

Jake Nikota, Allyson Banville, Laura Rose Goodwin, Dongmei Wu, Andrew Williams, Carole Lynn Yauk, Håkan Wallin, Ulla Vogel, Sabina Halappanavar

Open access · goldAbstract read
In one paragraph

Article in Particle and fibre toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. STAT6 suppression prevents bleomycin-induced dermal fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.Advances in experimental medicine and biology · 2022
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Jake NikotaEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Allyson BanvilleEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Laura Rose GoodwinEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Dongmei WuEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Andrew WilliamsEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Carole Lynn YaukEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada.
Håkan WallinDepartment of Biological and Chemical Work Environment, National Institute of Occupational Health, Oslo, Norway.
Ulla VogelNational Research Centre for the Working Environment, Lerso Parkallé 105, DK-2100, Copenhagen, Denmark.
Sabina HalappanavarEnvironmental Health Science and Research Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada. sabina.halappanavar@canada.ca.
Health Canada · CANational Institute of Occupational Health · NONational Research Centre for the Working Environment · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accumulation of MWCNTs in the lung environment leads to inflammation and the development of disease similar to pulmonary fibrosis in rodents. Adverse Outcome Pathways (AOPs) are a framework for defining and organizing the key events that comprise the biological changes leading to undesirable events. A putative AOP has been developed describing MWCNT-induced pulmonary fibrosis; inflammation and the subsequent healing response induced by inflammatory mechanisms have been implicated in disease progression. The objective of the present study was to address a key data gap in this AOP: empirical data supporting the essentiality of pulmonary inflammation as a key event prior to fibrosis. Specifically, Interleukin-1 Receptor1 (IL-1R1) and Signal Transducer and Activator of Transcription 6 (STAT6) knock-out (KO) mice were employed to target inflammation and the subsequent healing response using MWCNTs as a model pro-fibrotic stressor to determine whether this altered the development of fibrosis.

resultsWild type (WT) C57BL/6, IL-1R1 (KO) or STAT6 KO mice were exposed to a high dose of Mitsui-7 MWCNT by intratracheal administration. Inflammation was assessed 24 h and 28 days post MWCNT administration, and fibrotic lesion development was assessed 28 days post MWCNT administration. MWCNT-induced acute inflammation was suppressed in IL-1R1 KO mice at the 24 h time point relative to WT mice, but this suppression was not observed 28 days post exposure, and IL-1R1 KO did not alter fibrotic disease development. In contrast, STAT6 KO mice exhibited suppressed acute inflammation and attenuated fibrotic disease in response to MWCNT administration compared to STAT6 WT mice. Whole genome analysis of all post-exposure time points identified a subset of differentially expressed genes associated with fibrosis in both KO mice compared to WT mice.

conclusionThe findings support the essentiality of STAT6-mediated signaling in the development of MWCNT-induced fibrotic disease. The IL-1R1 KO results also highlight the nature of the inflammatory response associated with MWCNT exposure, and indicate a system with multiple redundancies. These data add to the evidence supporting an existing AOP, and will be useful in designing screening strategies that could be used by regulatory agencies to distinguish between MWCNTs of varying toxicity.

Indexed as

Adverse Outcome PathwaysAnimalsBronchoalveolar Lavage FluidFemaleInhalation ExposureInterleukin-1Mice, Inbred C57BLMice, KnockoutNanotubes, CarbonPulmonary FibrosisReceptors, Interleukin-1STAT6 Transcription FactorInterleukin-1Nanotubes, CarbonReceptors, Interleukin-1Stat6 protein, mouseSTAT6 Transcription FactorAdverse outcome pathwayFibrosisIl-1InflammationLung diseaseM2 MacrophageMulti-walled carbon nanotubesNanomaterialsSTAT6

Identifiers

PMID28903780
PMCPMC5598059
OpenAlexW2754449970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.